Major Breakthrough in Understanding Brain Aging

Scientists have identified a protein critical to the process of brain aging, and they’ve also figured out how to potentially inhibit its effects. This protein, known as FTL1, plays a significant role in aging within the hippocampus—a brain region that experiences notable decline over time.

Despite extensive efforts—seriously, people have tried a lot—there’s still no effective method to stop the relentless effects of aging on the human body. To tackle this massive challenge, researchers need a deep understanding of the underlying mechanisms, including the proteins and genes that contribute to aging and how they impact various body systems. This recent study makes strides in answering those long-held questions, particularly regarding the brain.

“It’s a hopeful time to be working on the biology of aging,” noted senior author Saul Villeda from the Bakar Aging Research Institute at UCSF.

The research compared older male mice, aged 18 to 22 months, with younger ones, roughly 2 to 3 months old. The team focused on the hippocampus—which, fun fact, resembles a seahorse and plays crucial roles in learning and memory—and identified only one protein that differed between the two age groups: FTL1.

The full name of FTL1 is ferritin light chain 1, and it’s important for long-term iron storage, which is essential for brain function. The researchers found its levels were higher in the older mice, suggesting that this increase reflects a change in brain iron metabolism as we age.

Further examination revealed that elevated FTL1 levels might also negatively influence the functioning of mitochondria, the powerhouses of our cells.

“Collectively, this body of work posits changes in mitochondria dynamics, and structural alterations to the inner membrane, as potential downstream mechanisms regulating the pro-aging effects of increased neuronal FTL1,” the authors mentioned.

To validate their findings, the researchers artificially raised FTL1 levels in the younger mice. The results were telling—their brains started to show signs of aging, as evidenced by poor performance in maze navigation and object recognition tasks.

In another experiment, when they boosted FTL1 levels in neuronal cells grown in Petri dishes, those cells exhibited far fewer branches, indicating a reduced capacity for connection.

Conversely, when they decreased FTL1 in older mice, nerve connections began to flourish again. Performance in cognitive tests improved significantly.

“It is truly a reversal of impairments,” Villeda remarked. “It’s not just about delaying symptoms.”

With these insights, the team aims to pave the way for innovative anti-aging therapies.

“We’re seeing more opportunities to alleviate the worst consequences of old age,” Villeda said.

This research not only seeks to address cognitive decline associated with aging but could have wider implications. Rare mutations of the Ftl1 gene in humans lead to a disorder called neuroferritinopathy, characterized by iron buildup in the brain, resulting in progressive difficulties like movement and speech. Additionally, there’s some correlation between altered iron metabolism and Alzheimer’s disease.

The researchers conclude, “Our data raise the exciting possibility that the beneficial effects of targeting neuronal FTL1 at old age may extend more broadly, beyond cognitive aging, to neurodegenerative disease conditions in older people.”

The findings have been published in Nature Aging.